CD28 and neoplasm: Studies have demonstrated that combining ICIs with CAR T cells or using CD19-CAR T cells engineered to express a PD-1/CD28 chimeric-switch receptor can significantly reduce tumor growth in PD-L1 positive lymphoma cells [20].